Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Annals of the Rheumatic Diseases 2008;67:438-442; doi:10.1136/ard.2007.083873
Copyright © 2008 BMJ Publishing Group Ltd & European League Against Rheumatism

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Shoenfeld, Y.
Right arrow Articles by Cervera, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shoenfeld, Y.
Right arrow Articles by Cervera, R.

EDITORIALS

Antiphospholipid syndrome dilemmas still to be solved: 2008 status

Yehuda Shoenfeld 1, Pier Luigi Meroni 2, Ricard Cervera 3

1 Department of Medicine "B" and Centre for Autoimmune Diseases, Sheba Medical Centre, Sackler Faculty of Medicine, Tel-Aviv University, Israel
2 Department of Internal Medicine, University of Milan Allergy, Clinical Immunology and Rheumatology Unit, IRCCS, Istituto Auxologico Italiano, Italy
3 Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain

Correspondence to:
Yehuda Shoenfeld, Sheba Medical Center, 52621 Tel-Hashomer, Israel; shoenfel@post.tau.ac.il

Accepted 3 January 2008

The first 150 words of the full text of this article appear below.

Extensive investigation of antiphospholipid syndrome (APS) has improved our knowledge of the disease, but raised new questions. Although the pathogenic role of antiphospholipid antibodies (aPL) is widely accepted, the fact that aPL induces thrombotic events only occasionally suggests the need for a "second hit" to display the thrombogenic effect. Infectious agents are thought to trigger autoantibody production through a molecular mimicry mechanism, but may also induce an inflammatory process that eventually favours clotting. The involvement of complement and cytokines in the pathogenesis further supports the role of inflammation in APS as well as the possibility for new therapeutic approaches. The question of whether other environmental triggers or a genetic individual susceptibility can behave as a second hit is still open. The clinical involvement of different organs and systems poses the question of whether the syndrome should be considered a true systemic autoimmune disease, rather than an acquired autoimmune coagulopathy. A . . . [Full text of this article]




This article has been cited by other articles:


Home page
Arch OphthalmolHome page
J. D. Brandt
Finding Risks for Glaucoma
Arch Ophthalmol, August 1, 2008; 126(8): 1138 - 1139.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & European League Against Rheumatism